z-logo
Premium
Significant differences in coeliac immunotoxicity of barley varieties
Author(s) -
Comino Isabel,
Real Ana,
GilHumanes Javier,
Pistón Fernando,
de Lorenzo Laura,
Moreno Ma de Lourdes,
LópezCasado Miguel Ángel,
Lorite Pedro,
Cebolla Ángel,
Torres Ma Isabel,
Barro Francisco,
Sousa Carolina
Publication year - 2012
Publication title -
molecular nutrition and food research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.495
H-Index - 131
eISSN - 1613-4133
pISSN - 1613-4125
DOI - 10.1002/mnfr.201200358
Subject(s) - gluten , coeliac disease , biology , food science , immunogenicity , hordeum vulgare , brewing , agronomy , cultivar , poaceae , microbiology and biotechnology , immune system , medicine , disease , immunology , fermentation
Scope The only treatment available for coeliac disease ( CD ) is a strict diet in which the intake of wheat, barley, rye, or oats is avoided. Barley is a major cereal crop, grown mainly for its use in brewing, and it has high nutritional value. The identification of varieties with a reduced toxicity profile may contribute to improve the diet, the quality of life and health of CD patients. Methods and results Searching for harmless barleys, we investigated accessions of malting and wild barley, used for developing new cultivated cereals. The CD toxicity profile of barleys was screened using G12 antibody and cell proliferation and IFN ‐γ release from peripheral blood mononuclear cells and intestinal biopsies from CD patients. We found a direct correlation between the reactivity with G 12 and the immunogenicity of the different barleys. Conclusion The malting barleys were less immunogenic, with reduced levels of toxic gluten, and were possibly less harmful to CD patients. Our findings could raise the prospect of breeding barley species with low levels of harmful gluten, and the attractive goal of developing nontoxic barley cultivars, always taking into account the C odex standard for foods for special dietary use for persons intolerant to gluten.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here